Valeriy Vladimirovich Breder, MD, PhD

CIO 2023-1 Four-year Overall Survival from the HIMALAYA Study of Tremelimumab + Durvalumab in Unresectable Hepatocellular Carcinoma

Purpose: In the primary analysis (data cut-off: 27 August 2021) of the phase 3 HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Re...

Yoon-Koo Kang , MD, PhD;

Charu Gupta , MSc;

Maria Reig , MD, PhD;

Peter R. Galle , MD, PhD;

Alejandra Negro , PhD;

Masatoshi Kudo , MD, PhD;

Bruno Sangro , MD, PhD;

George Tat-Ming Lau , MBBS, FRACP, MD, PhD;

Valeriy Vladimirovich Breder , MD, PhD;

Stephen Lam Chan , MD;

Robin Kate Kelley , MD;

Wattana Sukeepaisarnjaroen , MD;

Enrico De Toni , MD, PhD;

Junji Furuse , MD, PhD;

Lorenza Rimassa , MD;

Alexandra Heurgué , MD;

Vincent Tam , MD;

Tu Van Dao , MD, PhD;

Satheesh Chiradoni Thungappa , MD;

Yuriy Ostapenko , MD;

Mallory Makowsky , PharmD;

11/01/2023

Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240

BackgroundPembro received accelerated approval for second-line therapy in pts with advanced HCC, based on the phase 2, KEYNOTE-224 trial. KEYNOTE-240 was a randomized, phase 3 study of P...

Marcelo Garrido ;

Stephen Lam Chan , MD;

Jennifer J. Knox ;

Bruno Daniele ;

Scot Ebbinghaus ;

Erluo Chen ;

Abby B. Siegel ;

Julien Edeline ;

Baek-Yeol Ryoo ;

Ann-Lii Cheng , MD, PhD;

Philippe Merle ;

Masatoshi Kudo , MD, PhD;